Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Cash from Financing Activities (2019 - 2025)

Korro Bio (KRRO) has disclosed Cash from Financing Activities for 6 consecutive years, with $128000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 82.42% year-over-year to $128000.0, compared with a TTM value of $1.2 million through Sep 2025, down 99.42%, and an annual FY2024 reading of $69.4 million, down 63.06% over the prior year.
  • Cash from Financing Activities was $128000.0 for Q3 2025 at Korro Bio, up from $5000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $144.6 million in Q4 2023 and bottomed at -$2.2 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $14.4 million, with a median of $186000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 4014.29% in 2023, then skyrocketed 187755.56% in 2024.
  • Year by year, Cash from Financing Activities stood at $109000.0 in 2021, then plummeted by 318.35% to -$238000.0 in 2022, then soared by 60851.26% to $144.6 million in 2023, then crashed by 99.36% to $932000.0 in 2024, then crashed by 86.27% to $128000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for KRRO at $128000.0 in Q3 2025, $5000.0 in Q2 2025, and $172000.0 in Q1 2025.